Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD

Authors not listed

Insel Gruppe AG, University Hospital Bern · 2006

Abstract

This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg). An evaluation of the short term effects on CNV perfusion of this combined treatment is needed for better understanding of treatment effects.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-09 MST

Cite this

APA
Anonymous. (2006). Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD. <em>Insel Gruppe AG, University Hospital Bern</em>. https://clinicaltrials.gov/study/NCT00413829
Vancouver
Anonymous. Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD. Insel Gruppe AG, University Hospital Bern. 2006.
BibTeX
@misc{anon2006Openla, title = {Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD}, author = {Anonymous}, journal = {Insel Gruppe AG, University Hospital Bern}, year = {2006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings